Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I bring over 25+ years of leadership experience spanning pharmaceuticals, life sciences, FMCG, telecom, infrastructure, and global consulting, with the last decade deeply anchored in pharmaceutical and R&D-intensive environments. My core expertise sits at the intersection of strategic HR, innovation capability building, organizational transformation, and governance.

A significant part of my work has involved enabling R&D, manufacturing, and commercial organizations to scale talent in highly regulated, knowledge-intensive environments. I have led large transformations involving post-merger integration, workforce analytics, capability architecture, performance culture, and digital HR modernization, while partnering closely with boards and executive teams.

My perspective is shaped by working across both operating roles and advisory assignments, including supporting global research organizations on organizational design, talent systems, and people risk. This dual lens—practitioner and advisor—has given me a strong view on how human capital strategy can become a competitive differentiator, specifically in sectors where innovation, IP protection, and scientific talent are central to enterprise value.

Q2. Many global firms are moving R&D to India under the “China Plus One” strategy. How can companies protect their proprietary R&D culture from being commoditized by the massive influx of Global Capability Centers (GCCs)?

The real risk is not wage inflation or attrition — it is the commoditization of innovation.

Leading firms are protecting themselves in three ways:

First, they are treating culture as intellectual property. Innovation culture — how scientists collaborate, challenge assumptions, and make decisions — is becoming as important to protect as patents.

Second, they are moving GCCs beyond cost centers into innovation centers. The winners will be those using India not just for scale, but for differentiated scientific capability.

Third, they are protecting tacit knowledge. Competitive advantage usually lies in undocumented know-how that is hard to transfer. Companies are investing heavily in knowledge networks, mentorship ecosystems, and stronger internal mobility to preserve that edge.

Q3. Beyond simple attrition rates, how are companies using Predictive People Analytics to forecast “Skill Decay” within their R&D teams, and what is the measurable ROI of “reskilling-at-scale” initiatives compared to the cost of external hiring in the 2026 market?

Smart companies are shifting from tracking attrition to tracking capability erosion.

The emerging focus is skill decay — how quickly critical expertise becomes obsolete. In fast-moving R&D environments, that can be a major hidden risk.

Organizations are now using predictive analytics to monitor:

• Which critical skills may lose relevance over the next 18–24 months
• Which employees can be reskilled into adjacent high-demand roles
• How capability gaps may impact innovation speed and productivity

The case for reskilling is stronger than ever. Often, helping current employees learn new skills costs a lot less than bringing in new hires from outside—and it usually means people get up to speed faster and are more likely to stick around.

In 2026, leading companies are treating reskilling less as a talent initiative and more as a productivity lever.

Q4. With GenAI moving from pilot to “Invisible Infrastructure” in 2026, how are organizations auditing the algorithmic bias in automated screening for high-stakes R&D roles, and what “human-in-the-loop” protocols can be implemented?

The biggest risk with AI in hiring is not automation failure — it is invisible bias at scale.

Leading organizations are responding in three ways:

• They audit algorithms before deployment for hidden bias related to gender, geography, institutional pedigree, and other factors
• They insist on explainability. If an AI system cannot explain why, it ranked or screened out a candidate, it should not be used for critical decisions
• They keep humans accountable. Especially in specialist R&D hiring, AI should support decisions, not make them

Strong human-in-the-loop protocols include mandatory review of AI rejections, expert calibration panels, and periodic fairness audits involving HR, legal, and scientific leaders.

My view is simple: use AI for speed and pattern recognition but keep judgment human.

Q5. In an era of fluid, “gig-augmented” product development, what governance infrastructure can be implemented to ensure that decentralized teams navigate 2026’s heightened Global IP and Data Privacy regimes?

As innovation becomes decentralized, governance is becoming a competitive capability.

The strongest organizations are building five safeguards:

• Role-based access controls so external talent can access only what they need
• Digital traceability to track who contributed what across distributed teams
• Cross-border data governance to manage evolving privacy and regulatory exposure
• Modern IP contracts are designed for gig ecosystems, not traditional employment models
• Continuous risk monitoring using both technology controls and governance oversight

The bigger shift is that IP governance is moving from a legal function to a board-level risk issue.

Q6. If you were an investor looking at companies within the space, what critical question would you pose to their senior management?

I would ask one question: How durable is your innovation model under stress?

Because in today’s environment, innovation is being tested simultaneously by talent shortages, AI disruption, IP risk, and skill obsolescence.

I would want management to show evidence that they can:

• Sustain innovation productivity despite talent volatility
• Build critical capabilities faster than competitors
• Protect proprietary knowledge in distributed operating models
• Generate measurable returns from capability investments, not just R&D spend

In my view, the real valuation question is no longer “How much do you spend on innovation?” but “How resilient is the system that produces it?” That is where long-term value sits.